ARISTOTLE HF Subgroup Outcome Index (proxy – ABC-based)
- ARISTOTLE HF Subgroup Outcome Index: Rationale and clinical context
The original ARISTOTLE trial (apixaban vs warfarin) and its biomarker substudies showed that age, a clinical history of heart failure, and circulating biomarkers — notably NT-proBNP, high-sensitivity cardiac troponin, and growth differentiation factor-15 (GDF-15) — were among the strongest predictors of death and heart-failure related events in patients with atrial fibrillation. The ABC (Age, Biomarkers, Clinical history) risk framework was developed from ARISTOTLE data to quantify mortality risk in anticoagulated AF patients; this calculator implements a transparent proxy based on that approach to provide a relative HF-outcome index. For precise absolute risk estimates, one should use the original ABC equations or the published online ABC calculator (model coefficients/baseline hazard).
Reference:
Hijazi Z, et al. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (Age, Biomarkers, Clinical history) death risk score. (development from ARISTOTLE data).
Also see ARISTOTLE biomarker analyses addressing heart-failure events and biomarker prognostic value.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.